Skip to content
Top Globe News – Lifestyle
Author:
NEUROCRINE BIOSCIENCES, INC.
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules
May 18, 2026
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
May 18, 2026
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
May 7, 2026
Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia
May 6, 2026
Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026
May 5, 2026
Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment
May 4, 2026
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-‘2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist
May 4, 2026
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia
May 1, 2026
Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale
April 30, 2026
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
April 29, 2026
1
2
Next Page
→